Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA4 | P54764 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13329568 | 0.91 | EPHA4 (0.47) | EPHA4JAK2JAK1TYK2JAK3 | |
| SCHEMBL13329392 | 0.87 | EPHA4 (0.46) | EPHA4JAK2JAK1TYK2JAK3 | |
| SCHEMBL13329407 | 0.83 | HSD11B1 (0.36) | PTPN11DPP4HSD11B1 | |
| SCHEMBL13329387 | 0.83 | ALDH1A1 (0.43) | JAK2GAANPC1HPGDRAB9A | |
| SCHEMBL13329477 | 0.81 | EPHA4 (0.66) | EPHA4JAK2JAK1TYK2JAK3 | |
| SCHEMBL13329343 | 0.81 | EPHA4 (0.62) | EPHA4JAK2JAK1TYK2JAK3 | |
| SCHEMBL13329380 | 0.81 | EPHA4 (0.45) | EPHA4JAK2JAK1TYK2JAK3 | |
| SCHEMBL13329637 | 0.81 | EPHA4 (0.65) | EPHA4JAK2JAK1TYK2JAK3 | |
| SCHEMBL13329545 | 0.78 | EPHA4 (0.48) | EPHA4JAK1TYK2JAK3GAA | |
| SCHEMBL13329537 | 0.77 | EPHA4 (0.47) | EPHA4JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MERCK SHARP & DOHME CORP | 2010-05-06 | — | — | US | disclosed |
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MERCK SHARP & DOHME CORP | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | EPHA4, EPHA1, ERBB4 | EPHA4 1/4885JAK2 186/4885JAK1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.